Vixi Biotech

Vixi Biotech is disrupting the liver diagnostics market by commercializing an innovative blood test for diagnosing common liver diseases such as non-alcoholic steatohepatitis (NASH). Our flagship product, AccuNash™, is intended to be a low-cost, simple way to inform physicians on the severity of liver disease in broad populations worldwide. The goal is to easily and quickly characterize patients with liver disease using a standard blood sample. Vixi intends to offer a better alternative to existing methods, such as biopsy procedures, which are invasive, risky, expensive, and painful.